| Identification | Back Directory | [Name]
Indisulam | [CAS]
165668-41-7 | [Synonyms]
E-7070
D04522
ER-35744
INDISULAM
IndisulaM (E7070)
E7070;ER-35744;D04522
Indisulam >=98% (HPLC)
IndisulaM (E7070) (ER-35744)
N-(3-Chloro-1H-indol-7-yl)-1,4-benzenedisulfonamide
N1-(3-Chloro-1H-indol-7-yl)benzene-1,4-disulfonamide
1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)-
1,4-Benzenedisulfonamide, N1-(3-chloro-1H-indol-7-yl)- | [Molecular Formula]
C14H12ClN3O4S2 | [MDL Number]
MFCD00945325 | [MOL File]
165668-41-7.mol | [Molecular Weight]
385.85 |
| Chemical Properties | Back Directory | [Melting point ]
242-243 °C (decomp)(Solv: ethanol (64-17-5); water (7732-18-5)) | [Boiling point ]
668.9±65.0 °C(Predicted) | [density ]
1.663±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMSO : 100 mg/mL (259.17 mM; Need ultrasonic) | [form ]
powder | [pka]
8.14±0.30(Predicted) | [color ]
white to beige | [InChI]
InChI=1S/C14H12ClN3O4S2/c15-12-8-17-14-11(12)2-1-3-13(14)18-24(21,22)10-6-4-9(5-7-10)23(16,19)20/h1-8,17-18H,(H2,16,19,20) | [InChIKey]
SETFNECMODOHTO-UHFFFAOYSA-N | [SMILES]
C1(S(NC2C3=C(C=CC=2)C(Cl)=CN3)(=O)=O)=CC=C(S(N)(=O)=O)C=C1 |
| Hazard Information | Back Directory | [Uses]
Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15[1][2]. | [Definition]
ChEBI: Indisulam is a chloroindole that is 3-chloro-1H-indole substituted by a [(4-sulfamoylphenyl)sulfonyl]nitrilo group at position 7. It is a carbonic anhydrase inhibitor and a potential anti-cancer agent currently in clinical development. It has a role as an EC 4.2.1.1 (carbonic anhydrase) inhibitor and an antineoplastic agent. It is a chloroindole, a sulfonamide and an organochlorine compound. | [Biochem/physiol Actions]
Indisulam is a carbonic anhydrase inibitor and Antitumor CDK inhibitor. Indisulam targets the G1 phase of the cell cycle by depleting cyclin E. inducing p53 and p21, and inhibiting CDK2, causing a blockade in the G1/S transition. | [in vivo]
Indisulam (E7070, 12.5, 25, 50 (100) mg/kg) shows an antitumour spectrum in human cancer models[1]. | Animal Model: | Female BALB/c nu/nu mice aged 7 weeks (HCT116 colon, LX-1 lung, SW620 colon, HCT115 colon, PC-9 lung, DLD-1 colon and WiDr colon models)[1]. | | Dosage: | 12.5, 25, 50 (100) mg/kg. | | Administration: | IV daily for 4 days. | | Result: | Exhibited anti-tumor activity. |
| [storage]
Store at -20°C | [References]
[1] Ozawa Y, et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer. 2001 Nov;37(17):2275-82. DOI:10.1016/s0959-8049(01)00275-1
[2] Abbate F, et al. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23. DOI:10.1016/j.bmcl.2003.09.062 |
|
|